Austin, June 25, 2025 (GLOBE NEWSWIRE) -- Biosimulation Market Size & Growth Analysis:

“According to SNS Insider, the global Biosimulation Market was valued at USD 3.44 billion in 2023 and is projected to reach USD 14.05 billion by 2032, growing at a CAGR of 16.94% during the forecast period (2024–2032).”

High demand for predictive modelling and simulation tools in drug discovery and development is attributed to the rapid growth of the biosimulation market. Rising investment in R&D activities by business and biotechnology companies and a rise in acceptance of applications of AI and machine learning in biosimulation will drive the expansion of the market. Finally, the support by regulators for model-based drug development approaches and the need to reduce the costs and duration of clinical trials are major drivers globally for the uptake of biosimulation technology.

Get a Sample Report of Biosimulation Market@ https://www.snsinsider.com/sample-request/2200

The U.S. biosimulation market was estimated at USD 1.25 billion in 2023 and is expected to reach USD 5.08 billion by 2032, at a CAGR of 16.83% during the forecast period of 2024-2032

The North American biosimulation market is led by the U.S., which is a major contributor owing to its strong healthcare infrastructure, high pharmaceutical research and development expenditure, and the presence of major biotech and pharmaceutical players. The country hosts a significant number of clinical trials globally, which in turn fuels the demand for biosimulation tools.

Major Players Analysis Listed in this Report are:

• Certara, Inc. (Simcyp Simulator, Phoenix WinNonlin)
• Dassault Systèmes (BIOVIA Discovery Studio, BIOVIA Pipeline Pilot)
• Schrödinger, Inc. (Maestro, LiveDesign)
• Simulation Plus, Inc. (GastroPlus, ADMET Predictor)
• Rosa & Co. LLC (PhysioPD Research Platform, Model-Based Drug Development Services)
• Genedata AG (Genedata Screener, Genedata Profiler)
• Insilico Medicine (PandaOmics, Chemistry42)
• Chemical Computing Group (CCG) (MOE, PSILO)
• ACD/Labs (Advanced Chemistry Development) (Percepta Platform, MetaSense)
• Biomodels, LLC (Mechanistic Modeling Tools, QSP Platforms)
• Leadscope Inc. (Leadscope Model Applier, Leadscope Enterprise)
• DILIsym Services (a division of Simulations Plus) (DILIsym, NAFLDsym)
• Evidera (Thermo Fisher Scientific) (Pharmacometric Modeling Tools, Meta-analysis Services)
• Physiomics Plc (Virtual Tumour, Personalized Oncology Modeling)
• Genentech (Roche Group) (QSP Models, PK/PD Modeling Tools)
• Entelos, Inc. (PhysioLab Systems, Entelos PhysioLab Platform)
• Immunetrics, Inc. (Disease Modeling Platform, QSP Modeling Services)
• Applied BioMath, LLC (Applied BioMath QSP Platform, Applied BioMath Assess)

Biosimulation Market Report Scope

Segment Analysis:

Software Segment is Anticipated to Hold the Largest Share of the Biosimulation Market by Product

In 2023, the software segment held the largest market share with 61%, owing to the core application of software in predictive modeling, PK/PD simulations, and virtual clinical trials. These are software solutions that are critical in accelerating drug development while improving the accuracy of early-stage research. The increasing incorporation of AI and machine learning into biosimulation platforms has added more capabilities to these platforms and increased their attractiveness.

Based on Application, the Drug Development Segment Accounted for the Largest Share of the Biosimulation Market.

The drug development segment dominated the biosimulation market in 2023 with a 54% market share, due to the high utilization of biosimulation for drug design optimization, clinical trial failure reduction, and time-to-market acceleration. Biosimulation is considered an invaluable tool in predicting the behavior of drugs, assessing safety and efficacy, and simulating numerous clinical scenarios,  thus markedly reducing development costs.

By Therapeutic Area, the Biosimulation Market is Dominated by the Oncology Segment

In 2023, the oncology segment held the largest share of the biosimulation market as the global burden of cancer rises and the continual demand for innovative, targeted therapy. Biosimulation tools have been increasingly used in oncology to simulate tumor progression, optimize drug dosing, and predict patient-specific tumor phenotypes, which ultimately maximize treatment response. As the industry embraces biosimulation to reduce risk and make more informed decision-making, the competition among pharmaceutical companies is growing fiercer due to the complexity of cancer biology and the notoriously high failure rate of cancer drug trials.

For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https://www.snsinsider.com/request-analyst/2200

Biosimulation Market Segmentation

By Product

• Software
  • Molecular Modeling & Simulation Software
  • Clinical Trial Design Software
  • PK/PD Modeling and Simulation Software
  • Pbpk Modeling and Simulation Software
  • Toxicity Prediction Software
  • Others
• Services
  • Contract Services
  • Consulting
  • Others

By Application

• Drug Discovery & Development
• Disease Modeling
• Others

By Pricing Model

• License-based Model
• Subscription-based Model
• Service-based Model
• Pay Per Use Model

By Therapeutic Area

• Oncology
• Cardiovascular Disease
• Infectious Disease
• Neurological Disorders
• Others

By Deployment Model

• Cloud-based
• On-premise
• Hybrid Model

By End Use

• Life Sciences Companies
  • Pharmaceutical Companies
  • Biopharma Companies
  • Medical Device Companies
  • CROs/CDMOs
• Academic Research Institutions
• Others

Biosimulation Market is Expected to Register Fastest Growth in Asia-Pacific, North America Dominates.

The biosimulation market in North America accounted for the largest share in 2023, with a 48% market share, owing to the well-established healthcare infrastructure and large-scale presence of pharmaceutical and biotechnology companies in the region, and growing adoption of predictive modeling technologies in drug development. Moreover, the growing allocation towards R&D and regulatory initiatives from regulators such as the FDA has expedited the adoption of biosimulation solutions.

The region Asia-Pacific is estimated to grow at the highest CAGR during the forecast period, owing to a high clinical trial activity, increasing healthcare spending, and growing pharmaceutical manufacturing hubs in China, India, and South Korea. Politicians also drive adoption by modernizing healthcare systems and supporting biotech innovation.

Table of Contents – Major Key Points

1. Introduction

2. Executive Summary

3. Research Methodology

4. Market Dynamics Impact Analysis

5. Statistical Insights and Trends Reporting

6. Competitive Landscape

7. Biosimulation Market by Product

8. Biosimulation Market by Application

9. Biosimulation Market by Pricing Model

10. Biosimulation Market by Therapeutic Area

11. Biosimulation Market by Deployment Model

12. Biosimulation Market by End Use

13. Regional Analysis

14. Company Profiles

15. Use Cases and Best Practices

16. Conclusion

Buy a Single-User PDF of Biosimulation Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/2200

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.